Sign In
Buy VERU
$2.77
+0.440 (+18.88%)
At Close: Aug 10, 2026
Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
10:58am, Monday, 10'th Aug 2026
Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
06:30am, Monday, 10'th Aug 2026
-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients –
-- When issued U.S. patent protection until at least October 2044 -- -- Allowed patent adds to already issued enobosarm specific molecule polymorph composition of matter patents, as well as number of
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
08:30am, Monday, 03'rd Aug 2026
MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
08:30am, Thursday, 30'th Jul 2026
MIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
-- Phase 2b PLATEAU clinical trial exceeds targeted full enrollment of 200 patients — -- Interim analysis results on track for calendar Q1 ‘27-- MIAMI, FL, July 27, 2026 (GLOBE NEWSWIRE) -- Veru I
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
08:30am, Tuesday, 07'th Jul 2026
MIAMI, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
11:50am, Wednesday, 13'th May 2026
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
06:30am, Wednesday, 13'th May 2026
--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for i nterim analysis first quarter calendar year 2027 —
Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th
08:30am, Wednesday, 06'th May 2026
MIAMI, FL, May 06, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic an
Veru (NASDAQ:VERU) Share Price Crosses Below 200 Day Moving Average – Here’s Why
03:54am, Friday, 24'th Apr 2026
Veru Inc. (NASDAQ: VERU - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $2.64 and traded as low as $2.28
Veru (NASDAQ:VERU) Stock Passes Below 200 Day Moving Average – Should You Sell?
03:19am, Thursday, 16'th Apr 2026
Veru Inc. (NASDAQ: VERU - Get Free Report) shares passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $2.69 and traded as low as $2.39. Veru
Veru (NASDAQ:VERU) Shares Cross Below 200 Day Moving Average – Here’s Why
02:40am, Friday, 27'th Mar 2026
Veru Inc. (NASDAQ: VERU - Get Free Report)'s stock price passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $2.81 and traded as low as $2.19.
-- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
01:54pm, Wednesday, 11'th Feb 2026
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
